DIABETES MONITORING DEVICES MARKET ANALYSIS

Market News

Recent Developments

New product launches

• On December 2022, Dexcom G7, a global leader in real-time continuous glucose monitoring for people with diabetes; announced that U.S. Food and Drug Administration (FDA) cleared the next-generation Dexcom G7 continuous glucose moitoring (CGM) system for people with all types of diabetes ages two years and older.
• In June 2022, Abbott, a global healthcare company which provides life-changing technologies which product such as diagnostics, medical devices, nutritionals, and branded generic medicines; announced that it is developing a new biowearable that will continuously monitor glucose and ketone levels in one sensor.
• In September, 2023, Medtronic Plc., a global healthcare technology company, announced Conformité Européenne (CE) mark approval for its new all-in-one, disposable Simplera continuous glucose monitor (CGM) featuring a simple and two-step insertion process. The company’s newest no-fingerstick sensor does not require over tape and is seamlessly integrated with the InPen smart insulin pen, which provides real-time, personalized dosing guidance to help simplify diabetes management.

Acquisition and partnerships

• In August 2022, Abbott, a global healthcare company which provides life-changing technologies which product such as diagnostics, medical devices, nutritionals, and branded generic medicines; and WW International, Inc., a human-centric technology company powered by the world’s leading commercial weight management program; announced a strategic partnership that will help to provide people living with diabetes, better understand and manage their diabetes and weight. The companies are working together to integrate WeightWatchers’ diabetes-tailored weight management program with Abbott’s potfolio of FreeStyle Libre products to create a seamless mobile experience that will give people, living with diabetes, the information and insights, that are needed to make healthy adjustments to their diet, by improving their glucose levels, and, ultimately, gain more control of their health.
• In November 2022, Senseonics Holdings, a medical technology company, focused on development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, and Ascensia Diabetes Care, a global diabetes care company; developer of CONTOUR blood glucose monitoring (BGM) system portfolio and exclusive distributor of Eversense CGM Systems, launched a collaboration with the Nurse Practitioner group (NPG), a leader in multidisciplinary health services and medical staffing solutions.